EFTR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EFTR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
eFFECTOR Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-2.16.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
For the Biotechnology subindustry, eFFECTOR Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where eFFECTOR Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
eFFECTOR Therapeutics (OTCPK:EFTR) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of eFFECTOR Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Sr One Capital Fund I Aggregator Lp | 10 percent owner | C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011 |
Christopher B Ehrlich | director, 10 percent owner, officer: Chief Executive Officer | 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158 |
Mayank Gandhi | officer: Chief Business Officer | 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
Douglas J Warner | officer: Chief Medical Officer | C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075 |
Presidio Management Group X Llc | 10 percent owner | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
Carlyle Group Inc. | 10 percent owner | C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
Carlyle Genesis Uk Llc | 10 percent owner | C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004 |
Carlyle Investment Management Llc | 10 percent owner | 1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004 |
Carlyle Holdings I L.p. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Carlyle Holdings I Gp Inc. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Tc Group, Llc | 10 percent owner | C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004 |
Cg Subsidiary Holdings L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
Carlyle Holdings I Gp Sub L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Gallagher Brian M. Jr. | director, 10 percent owner | C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139 |
Stephen T Worland | director, officer: President and Chief Executive | 9050 CAMINO SANTA FE, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired • 10-24-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 02-21-2023
By sperokesalga sperokesalga • 05-26-2023
By Stock market mentor Stock market mentor • 01-30-2023
By sperokesalga sperokesalga • 04-26-2023
By GuruFocus Research • 02-06-2024
By Value_Insider Value_Insider • 10-31-2022
By Marketwired • 08-08-2023
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.